Time trends in the use of curative treatment in men 70 years and older with nonmetastatic prostate cancer
DOI:
https://doi.org/10.2340/1651-226X.2024.26189Keywords:
Prostate cancer, management, age, mortality, SwedenAbstract
Background: Undertreatment of otherwise healthy men in their seventies with prostate cancer has been reported previously.
Material and methods: Using information in a Swedish prostate cancer research database, patterns of management and cancer-specific mortality were compared across age groups in over 70,000 men diagnosed with intermediate- or high-risk nonmetastatic prostate cancer between 2008 and 2020. Crude probabilities of death were estimated non-parametrically. Staging procedures, primary treatment, and cancer death were compared using regression models, adjusting for patient and tumor characteristics.
Results: During the study period, the proportion of men treated with curative intent increased in ages 70–74 (intermediate-risk from 45% to 72% and high-risk from 49% to 84%), 75–79 (intermediate-risk from 11% to 52% and high-risk from 12% to 70%), and 80–84 years (intermediate-risk from < 1% to 14% and high-risk from < 1% to 30%). Older age was associated with lower likelihoods of staging investigations and curative treatment, also after adjustment for tumor characteristics and comorbidity. Men treated with curative intent and those initially managed conservatively had lower crude risks of prostate cancer death than men receiving androgen deprivation treatment (ADT). In adjusted analyses, ADT was associated with higher prostate cancer mortality than curative treatment across ages and risk groups. Among men managed conservatively, prostate cancer mortality was higher in ages 70 and above.
Interpretation: Use of curative treatment increased substantially in older men with prostate cancer between 2008 and 2020. Our findings suggest reduced age-bias and under-treatment, likely reflecting improved individualized decision-making and adherence to guidelines recommending more active management of older men.
Downloads
References
Bratt O, Folkvaljon Y, Eriksson MH, et al. Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 2015;68:53–8. https://doi.org/10.1016/j.eururo.2014.12.026 DOI: https://doi.org/10.1016/j.eururo.2014.12.026
Vernooij RWM, Van Oort I, De Reijke TM, Aben KKH. Nationwide treatment patterns and survival of older patients with prostate cancer. J Geriatr Oncol. 2019;10:252–8. https://doi.org/10.1016/j.jgo.2018.06.010 DOI: https://doi.org/10.1016/j.jgo.2018.06.010
Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol. 2003;21:3580–7. https://doi.org/10.1200/JCO.2003.02.046 DOI: https://doi.org/10.1200/JCO.2003.02.046
Colorectal Cancer Collaborative Group. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet. 2000;356:968–74. https://doi.org/10.1016/S0140-6736(00)02713-6 DOI: https://doi.org/10.1016/S0140-6736(00)02707-0
Bernardi D, Errante D, Tirelli U, Salvagno L, Bianco A, Fentiman IS. Insight into the treatment of cancer in older patients: developments in the last decade. Cancer Treat Rev. 2006;32:277–88. https://doi.org/10.1016/j.ctrv.2006.03.005 DOI: https://doi.org/10.1016/j.ctrv.2006.03.005
Everaerts W, Van Rij S, Reeves F, Costello A. Radical treatment of localised prostate cancer in the elderly. BJU Int. 2015;116:847–52. https://doi.org/10.1111/bju.13128 DOI: https://doi.org/10.1111/bju.13128
Foster JA, Salinas GD, Mansell D, Williamson JC, Casebeer LL. How does older age influence oncologists’ cancer management? Oncologist. 2010;15:584–92. https://doi.org/10.1634/theoncologist.2009-0198 DOI: https://doi.org/10.1634/theoncologist.2009-0198
Lunardi P, Ploussard G, Grosclaude P, et al. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. World J Urol. 2017;35:587–93. https://doi.org/10.1007/s00345-016-1900-9 DOI: https://doi.org/10.1007/s00345-016-1900-9
Vatandoust S, Kichenadasse G, O’Callaghan M, et al. Localised prostate cancer in elderly men aged 80–89 years, findings from a popula-tion-based registry. BJU Int. 2018;121:48–54. https://doi.org/10.1111/bju.14228 DOI: https://doi.org/10.1111/bju.14228
Pettersson A, Robinson D, Garmo H, Holmberg L, Stattin P. Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study. Ann Oncol. 2018;29:377–85. https://doi.org/10.1093/annonc/mdx742 DOI: https://doi.org/10.1093/annonc/mdx742
Wilson JM, Dearnaley DP, Syndikus I, et al. The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. Int J Radiat Oncol. 2018;100:1179–89. https://doi.org/10.1016/j.ijrobp.2018.01.016 DOI: https://doi.org/10.1016/j.ijrobp.2018.01.016
Statistics Sweden. Mean remaining life expectancy in men ages 70–90, 2008–2021. Ettårig livslängdstabell för hela riket efter kön och ålder. År 1960–2021 [Internet]. 2022 [cited 09-12-2022]. Available from: https://www.statistikdatabasen.scb.se/sq/132299
Sanda MG, Cadeddu JA, Kirkby E, et al. Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol. 2018;199:683–90. https://doi.org/10.1016/j.juro.2017.11.095 DOI: https://doi.org/10.1016/j.juro.2017.11.095
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65:124–37. https://doi.org/10.1016/j.eururo.2013.09.046 DOI: https://doi.org/10.1016/j.eururo.2013.09.046
Regionala cancercentrum i samverkan. Nationellt vårdprogram Prostatacancer [Internet]. 2022 [cited 15-12-2022]. Available from: https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/prostatacancer/vardprogram/nvp-prostatacancer.pdf
Daskivich TJ. The importance of accurate life expectancy prediction in men with prostate cancer. Eur Urol. 2015;68:766–7. https://doi.org/10.1016/j.eururo.2015.03.020 DOI: https://doi.org/10.1016/j.eururo.2015.03.040
National Prostate Cancer Register (NPCR) of Sweden. Distribution of risk classification for men with prostate cancer [Internet]. 2024 [cited 17-01-2024]. Available from: https://statistik.incanet.se/npcr/
Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: the national prostate cancer register of Sweden and prostate cancer data base Sweden 2.0. Int J Epidemiol. 2013;42:956–67. https://doi.org/10.1093/ije/dys068 DOI: https://doi.org/10.1093/ije/dys068
Charlson ME, Pompei P, Ales KL, MacKenzie RC. A new method of classifying prognostic in longitudinal studies: development. J Chron Dis. 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8 DOI: https://doi.org/10.1016/0021-9681(87)90171-8
Ludvigsson JF, Appelros P, Askling J, et al. Adaptation of the Charlson comorbidity index for register-based research in Sweden. Clin Epi-demiol. 2021;13:21–41. https://doi.org/10.2147/CLEP.S282475 DOI: https://doi.org/10.2147/CLEP.S282475
Gedeborg R, Sund M, Lambe M, et al. An aggregated comorbidity measure based on history of filled drug prescriptions: development and evaluation in two separate cohorts. Epidemiology. 2021;32:607–15. https://doi.org/10.1097/EDE.0000000000001358 DOI: https://doi.org/10.1097/EDE.0000000000001358
Matthes KL, Pestoni G, Korol D, Van Hemelrijck M, Rohrmann S. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: a population-based retrospective cohort study. Urol Oncol. 2018;36:309.e15–23. https://doi.org/10.1016/j.urolonc.2018.02.016 DOI: https://doi.org/10.1016/j.urolonc.2018.02.016
Boehm K, Dell’Oglio P, Tian Z, et al. Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. World J Urol. 2017;35:1031–6. https://doi.org/10.1007/s00345-016-1963-7 DOI: https://doi.org/10.1007/s00345-016-1963-7
Hamilton AS, Fleming ST, Wang D, et al. Clinical and demographic factors associated with receipt of non guideline-concordant initial ther-apy for nonmetastatic prostate cancer. Am J Clin Oncol. 2016;39:55–63. https://doi.org/10.1097/COC.0000000000000017 DOI: https://doi.org/10.1097/COC.0000000000000017
Hoffman KE. Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity. Sem Radiat Oncol. 2012;22:284–94. https://doi.org/10.1016/j.semradonc.2012.05.005 DOI: https://doi.org/10.1016/j.semradonc.2012.05.005
Bechis SK, Carroll PR, Cooperberg MR. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011;29:235–41. https://doi.org/10.1200/JCO.2010.30.2075 DOI: https://doi.org/10.1200/JCO.2010.30.2075
Knipper S, Pecoraro A, Palumbo C, et al. The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes Contr. 2020;31:283–90. https://doi.org/10.1007/s10552-020-01273-5 DOI: https://doi.org/10.1007/s10552-020-01273-5
Bandini M, Pompe RS, Marchioni M, et al. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World J Urol. 2018;36:7–13. https://doi.org/10.1007/s00345-017-2102-9 DOI: https://doi.org/10.1007/s00345-017-2102-9
Orrason AW, Styrke J, Garmo H, Stattin P. Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden. BJU Int. 2023;131:486–93. https://doi.org/10.1111/BJU.15891 DOI: https://doi.org/10.1111/bju.15891
Additional Files
Published
How to Cite
License
Copyright (c) 2024 Frida E Lundberg, David Robinson, Ola Bratt, Giuseppe Fallara, Mats Lambe, Anna L. V. Johansson
This work is licensed under a Creative Commons Attribution 4.0 International License.
Funding data
-
Cancerfonden
Grant numbers 17-0611
